India
· Delayed Price · Currency is INR Ipca Laboratories Statistics
Total Valuation
Ipca Laboratories has a market cap or net worth of INR 403.40 billion. The enterprise value is 423.19 billion.
| Market Cap | 403.40B |
| Enterprise Value | 423.19B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | Aug 6, 2024 |
Share Statistics
Ipca Laboratories has 253.70 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Shares Outstanding | 253.70M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 8.71% |
| Owned by Institutions (%) | 44.84% |
| Float | 135.44M |
Valuation Ratios
The trailing PE ratio is 69.94 and the forward PE ratio is 42.13. Ipca Laboratories's PEG ratio is 1.91.
| PE Ratio | 69.94 |
| Forward PE | 42.13 |
| PS Ratio | 4.91 |
| PB Ratio | 6.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.91 |
Enterprise Valuation
| EV / Earnings | 73.37 |
| EV / Sales | 5.15 |
| EV / EBITDA | 31.24 |
| EV / EBIT | 43.06 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 1.06 |
| Debt / FCF | n/a |
| Interest Coverage | 7.59 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 7.45% |
| Revenue Per Employee | 4.74M |
| Profits Per Employee | 332,720 |
| Employee Count | 17,335 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +64.27% |
| 50-Day Moving Average | 1,420.80 |
| 200-Day Moving Average | 1,264.64 |
| Relative Strength Index (RSI) | 69.34 |
| Average Volume (20 Days) | 397,820 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ipca Laboratories had revenue of INR 82.13 billion and earned 5.77 billion in profits. Earnings per share was 22.73.
| Revenue | 82.13B |
| Gross Profit | 52.38B |
| Operating Income | 9.87B |
| Pretax Income | 8.77B |
| Net Income | 5.77B |
| EBITDA | 13.42B |
| EBIT | 9.87B |
| Earnings Per Share (EPS) | 22.73 |
Balance Sheet
The company has 8.54 billion in cash and 14.38 billion in debt, giving a net cash position of -5.84 billion or -23.02 per share.
| Cash & Cash Equivalents | 8.54B |
| Total Debt | 14.38B |
| Net Cash | -5.84B |
| Net Cash Per Share | -23.02 |
| Equity (Book Value) | 77.27B |
| Book Value Per Share | 249.59 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 63.77%, with operating and profit margins of 12.02% and 7.02%.
| Gross Margin | 63.77% |
| Operating Margin | 12.02% |
| Pretax Margin | 10.68% |
| Profit Margin | 7.02% |
| EBITDA Margin | 16.34% |
| EBIT Margin | 12.02% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 0.25%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 0.25% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | 0.24% |
| Earnings Yield | 1.43% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on January 10, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jan 10, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |